Pneumonia in HIV-infected persons: Increased risk with cigarette smoking and treatment interruption

American Journal of Respiratory and Critical Care Medicine

Volumn 178, Issue 6, 2008, Pages 630-636

  Gordin, Fred M ^a,m   Roediger, Mollie P ^b   Girard, Pierre Marie ^c   Lundgren, Jens D ^d   Miro, Jose M ^e   Palfreeman, Adrian ^f,g   Rodriguez Barradas, Maria C ^h   Wolff, Marcelo J ⁱ   Easterbrook, Philippa J ^j   Clezy, Kate ^k   Slater, Leonard N ^l  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c HÔPITAL SAINT ANTOINE   (France)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e UNIVERSITY OF BARCELONA   (Spain)

^f UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^g MEDICAL RESEARCH COUNCIL   (United Kingdom)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CHILE   (Chile)

^j KING'S COLLEGE LONDON   (United Kingdom)

^k UNIVERSITY OF NEW SOUTH WALES   (Australia)

^l UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^m VETERANS AFFAIRS MEDICAL CENTER   (United States)

more..

Author keywords

Bacterial infections; HIV; Pneumonia; Smoking

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CIGARETTE SMOKING; CLINICAL FEATURE; CLINICAL TRIAL; CONFIDENCE INTERVAL; FEMALE; FOLLOW UP; HAZARD ASSESSMENT; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT INTERRUPTION;

ADULT; ANTI-RETROVIRAL AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PNEUMONIA, STAPHYLOCOCCAL; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SMOKING;

EID: 51849168188     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200804-617OC     Document Type: Article

References (29)

1. National Heart, Lung, and Blood Institute Workshop. Special report: pulmonary complications of the acquired immunodeficiency syndrome. N Engl J Med 1984;310:1682-1688.
2. Polsky B, Gold JW, Whimbey E, Dryjanski J, Brown AE, Schiffman G, Armstrong D. Bacterial pneumonia in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1986;104:38-41.
3. Selwyn PA, Feingold AR, Hartel D, Schoenbaum EE, Alderman MH, Klein RS, Friedland GH. Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS. AIDS 1988;2:267-272.
4. Hirschtick RE, Glassroth J, Jordan MC, Wilcosky TC, Wallace JM, Kvale PA, Markowitz N, Rosen MJ, Mangura BT, Hopewell PC; The Pulmonary Complications of HIV Infection Study Group. Bacterial pneumonia in persons infected with the human immunodeficiency virus. N Engl J Med 1995;333:845-851.
5. Boschini A, Smacchia C, Di Fine M, Schiesari A, Ballarini P, Arlotti M, Gabrielli C, Castellani G, Genova M, Pantani P, et al. Community-acquired pneumonia in a cohort of former injection drug users with and without human immunodeficiency virus infection: incidence, etiologies, and clinical aspects. Clin Infect Dis 1996;23:107-113.
6. Witt DJ, Craven DE, McCabe WR. Bacterial infections in adult patients with the acquired immune deficiency syndrome (AIDS) and AIDS-related complex. Am J Med 1987;82:900-906.
7. Nagappan V, Kazanjian P. Bacterial infections in adult HIV-infected patients. HIV Clin Trials 2005;6:213-228.
8. Centers for Disease Control. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41.
9. Cordero E, Pachón J, Rivero A, Girón JA, Gómez-Mateos J, Merino MD, Torres-Tortosa M, Gonzalez-Serrano M, Aliaga L, Collado A, et al.; for the Grupo Andaluz Para el Estudio de las Enfermedades Infecciosas. Community-acquired bacterial pneumonia in human immunodeficiency virus-infected patients. Am J Respir Crit Care Med 2000;162:2063-2068.
10. Sullivan JH, Moore RD, Keruly JC, Chaisson RE. Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection. Am J Respir Crit Care Med 2000;162:64-67.
11. Burns DN, Hillman D, Neaton JD, Sherer R, Mitchell T, Capps L, Vallier WG, Thurnherr MD, Gordin FM; for the Terry Beirn Community Programs for Clinical Research on AIDS. Cigarette smoking, bacterial pneumonia, and other clinical outcomes in HIV-1 infection. J Acquir Immune Defic Syndr 1996;13:374-383.
12. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-2296.
13. Gordin F, Roediger M, Clezy K, Easterbrook PJ, Girard P, Lundgren J, Miro JM, Palfreeman A, Rodriguez-Barradas M, Slater L, et al.; for the SMART Study Group and INSIGHT Network. An increased risk of bacterial pneumonia in patients interrupting antiretroviral treatment: results from the SMART study. Presented at the Fourth IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, July 2007.
14. Wallace JM, Hansen NI, Lavange L, Glassroth J, Browdy BL, Rosen MJ, Kvale PA, Mangura BT, Reichman LB, Hopewell PC; The Pulmonary Complications of HIV Infection Study Group. Respiratory disease trends in the pulmonary complications of HIV infection study cohort. Am J Respir Crit Care Med 1997;155:72-80.
15. Kuller L; SMART Study Group. Elevated levels of interleukin-6 and D-dimer are associated with an increased risk of death in patients with HIV. Presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, February 2008.
16. Arcavi L, Benowitz NL. Cigarette smoking and infection. Arch Intern Med 2004;164:2206-2216.
17. Tumbarello M, Tacconelli E, deGaetano K, Ardito F, Pirronti T, Cauda R, Ortona L. Bacterial pneumonia in HIV-infected patients: analysis of risk factors and prognostic indicators. J Acquir Immune Defic Syndr 1998;18:39-45.
18. Crothers K, Griffith TA, McGinnis KA, Rodriguez-Barradas MC, Leaf DA, Weissman S, Gibert CL, Butt AA, Justice AC. The impact of cigarette smoking on mortality, quality of life, and comorbid illness among HIV-positive veterans. J Gen Intern Med 2005;20:1142-1145.
19. Rimland D, Navin TR, Lennox JL, Jernigan JA, Kaplan J, Erdman D, Morrison CJ, Wahlquist SP; Pulmonary Opportunistic Infection Study Group. Prospective study of etiologic agents of community-acquired pneumonia in patients with HIV infection. AIDS 2002;16:85-95.
20. Benito N, Rañó A, Moreno A, González J, Luna M, Agustí C, Danés C, Pumarola T, Miró JM, Torres A, et al. Pulmonary infiltrates in HIV-infected patients in the highly active antiretroviral therapy era in Spain. J Acquir Immune Defic Syndr 2001;27:35-43.
21. Janoff EN, Breiman RF, Daley CL, Hopewell PC. Pneumococcal disease during HIV infection: epidemiologic, clinical, and immunologic perspectives. Ann Intern Med 1992;117:314-324.
22. Barry PM, Zetola N, Keruly JC, Moore RD, Gebo KA, Lucas GM. Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990-2003. AIDS 2006;20:437-444.
23. Jordano Q, Falcó V, Almirante B, Planes AM, del Valle O, Ribera E, Len O, Pigrau C, Pahissa A. Invasive Pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 2004;38:1623-1628.
24. Heffernan RT, Barrett NL, Gallagher KM, Hadler JL, Harrison LH, Reingold AL, Khoshnood K, Holford TR, Schuchat A. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. J Infect Dis 1995;191:2038-2045.
25. Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE; Adult and Adolescent Spectrum of HIV Disease Project. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis 2001;32:794-800.
26. Breiman RF, Keller DW, Phelan MA, Sniadack DH, Stephens DS, Rimland D, Farley MM, Schuchat A, Reingold AL. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected persons. Arch Intern Med 2000;160:2633-2638.
27. Watera C, Nakiyingi J, Miiro G, Miiro G, Muwonge R, Whitworth JAG. 23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort. AIDS 2004;18:1210-1213.
28. Feikin DR, Feldman C, Schuchat A, Janoff EN. Global strategies to prevent bacterial pneumonia in adults with HIV disease. Lancet 2004;4:445-455.
29. Aberg JA, Gallant JE, Anderson J, Oleske JM, Libman H, Currier JS, Stone VE, Kaplan JE. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2004;39:609-628.